Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Good Prognosis Microscopic Polyangiitis
NCT03920722Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in microscopic polyangiitis (MPA), sponsored by Assistance publique - Hôpitaux de Paris. Started Oct 2020; status: completed.
02
Drugs
rituximab
03
Conditions
microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT03920722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920722.